Last reviewed 2026-04-20 · How we verify

Myoview (TETROFOSMIN)

At a glance

Approved indications

No approved indications tracked.

Common side effects

• angina
• flushing
• dyspnea
• headache
• abdominal pain
• dizziness
• palpitations
• nausea
• hypotension
• pain
• hypertension
• vomiting

Key clinical trials

• Evaluation of the Diagnostic Performance of Dynamic Myocardial Perfusion Scintigraphy in Comparison With Invasive Intracoronary FFR Measurement, in the Assessment of Significant Residual Coronary Stenosis After Acute Coronary Syndrome: Dyna-MI Pilot Study. (NA)
• Multi-Center Evaluation of Feasibility of SPECT Measurement of Myocardial Blood Flow and Reserve
• Cadmium-zinc-telluride (CZT) Imaging of Myocardial Blood Flow (MBF) (SPECT MBF) (NA)
• A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT) (PHASE2)
• Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI) (PHASE3)
• Cardiac Autonomic Function in Women with Microvascular Coronary Dysfunction (NA)
• A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD. (PHASE3)
• Technical Performance Assessment of Tc-99m Tetrofosmin for Differentiation of Recurrence vs Radiation Necrosis in Patients With Glioma (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Myoview CI brief — competitive landscape report
• Myoview updates RSS · CI watch RSS